Invention Grant
US08772028B2 CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
有权
体外产生的CD34 + CD7 + CD5 + CD1a-人祖细胞T细胞和使用方法
- Patent Title: CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
- Patent Title (中): 体外产生的CD34 + CD7 + CD5 + CD1a-人祖细胞T细胞和使用方法
-
Application No.: US13127490Application Date: 2009-11-06
-
Publication No.: US08772028B2Publication Date: 2014-07-08
- Inventor: Juan Carlos Zuniga-Pflucker , Geneve Awong , Ross La Motte-Mohs
- Applicant: Juan Carlos Zuniga-Pflucker , Geneve Awong , Ross La Motte-Mohs
- Applicant Address: CA Toronto, Ontario
- Assignee: Sunnybrook Health Sciences Centre
- Current Assignee: Sunnybrook Health Sciences Centre
- Current Assignee Address: CA Toronto, Ontario
- Agency: Bereskin & Parr LLP/S.E.N.C.R.L., s.r.l.
- Agent Micheline Gravelle
- International Application: PCT/CA2009/001601 WO 20091106
- International Announcement: WO2010/051634 WO 20100514
- Main IPC: C12N5/00
- IPC: C12N5/00 ; C12N15/00 ; C12N5/0789 ; C12N5/0783 ; C12N5/071
Abstract:
Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
Public/Granted literature
- US20110274671A1 HUMAN PROGENITOR T-CELLS Public/Granted day:2011-11-10
Information query
